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ARTIGO/ARTICLE

The activity of azithromycin against Leishmania (Viannia)
braziliensis and Leishmania (Leishmania) amazonensis
in the golden hamster model
A atividade da azitromicina contra a Leishmania (Viannia) braziliensis e a
Leishmania (Leishmania) amazonensis no modelo golden hamster
Ángel Sinagra1, Concepción Luna1, David Abraham2, Maria del Carmen Iannella3,
Adelina Riarte1 and Alejandro J. Krolewiecki4, 5

Abstract
New therapeutic alternatives against leishmaniasis remain a priority. The activity of azithromycin against Leishmania (Leishmania) major
has been previously demonstrated. Different responses among species of Leishmania make species-specific drug screening necessary. The
activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis was evaluated in golden hamsters
infected through footpad injections of metacyclic promastigotes, and compared with untreated controls and animals treated with meglumine
antimoniate. Footpad thickness, lesion cultures and dissemination sites were analyzed. Treatment of golden hamsters with oral azithromycin
at 450mg/kg had no activity against infections with Leishmania (Leishmania) amazonensis. For infections due to Leishmania (Viannia) braziliensis,
azithromycin demonstrated significant activity relative to untreated controls, but inferior to meglumine antimoniate, for controlling lesion
size. Neither drug was able to totally eliminate parasites from the lesions. It was concluded that azithromycin has activity against Leishmania
(Viannia) braziliensis but not against Leishmania (Leishmania) amazonensis in this model.
Key-words: Leishmania Viannia braziliensis. Leishmania Leishmania amazonensis. Azithromycin. Hamster.
Resumo
Novas alternativas terapêuticas contra a leishmaniose são ainda uma prioridade. A atividade da azitromicina contra a Leishmania (Leishmania)
major foi anteriormente demonstrada. Diferentes respostas entre as espécies de Leishmania fazem com que um screening de drogas específicas
para espécies seja necessário. A atividade da azitromicina contra a Leishmania (Viannia) braziliensis e a Leishmania (Leishmania) amazonensis
foi avaliada em Golden hamsters infectados a través de injeções de promastigotas metacíclicas e comparando com controles sem tratamento
e animais tratados com antimoniato de N-metil-glucamina. Foram analisadas a espessura da pata, a cultura das lesões e disseminação para
órgãos internos. A azitromicina oral em dose de 450mg/kg não teve atividade contra a infecção por Leishmania ( Leishmania) amazonensis. Para
infecções devidas à Leishmania (Viannia) braziliensis, a azitromicina teve uma atividade significativa em relação aos controles sem tratamento,
mas foi inferior ao antimoniato de N-metil-glucamina quanto ao controle do tamanho das lesões. Nenhuma das drogas conseguiu eliminar
totalmente os parasitos das lesões. Foi concluído que a azitromicina tem atividade contra Leishmania (Viannia) braziliensis, mas não tem
atividade contra Leishmania (Leishmania) amazonensis neste modelo.
Palavras-chaves: Leishmania Viannia braziliensis. Leishmania Leishmania amazonensis. Azitromicina. Hamster.

The search for new therapies against leishmaniasis in its
different forms continues to be a clinical priority. Leishmania
(Viannia) braziliensis has been identified as the causative
agent of most cases of cutaneous and mucosal leishmaniasis
in Argentina, although a role for Leishmania (Leishmania)
amazonensis and Leishmania (Viannia) guyanensis has

recently been described in a minority of cases3 8. Infection of
golden hamsters with Leishmania (Viannia) braziliensis results
in local lesions and dissemination13. In the case of infections
with Leishmania (Leishmania) amazonensis, golden hamsters
develop florid lesions at the inoculation site that tend to grow
chronically with dissemination to metastatic foci. Treatments with
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meglumine antimoniate are able to control but not to sterilize the
lesions caused by both Leishmania (Viannia) braziliensis and
Leishmania (Leishmania) amazonensis 2 11.
The activity of azithromycin against Leishmania (Leishmania)
major in vitro and in BALB/cByJ mice has been previously
demonstrated. In vitro, azithromycin significantly reduced
parasite numbers in cell-free cultures, the number of amastigotes
per macrophage and the number of infected macrophages.
Treatment of BALB/cByJ mice with azithromycin caused diminished
lesion size and parasite load6 7.
Azithromycin has a benign toxicity profile, good tolerance
in pediatric populations, oral and parenteral formulations and
a lack of contraindications during pregnancy (FDA category
B)14. This drug also has preferential active concentration in
macrophages5.
The objective of this study was to determine the effect of
azithromycin on Leishmania (Viannia) braziliensis and
Leishmania (Leishmania) amazonensis infections of golden
hamsters using experimental systems designed for each species.
Material and Methods
Drugs. Azithromycin (Zitromax™, Pfizer) powder was mixed
in water to a dilution of 40mg/ml. Meglumine antimoniate (Lazar,
Argentina) was used from vials containing 5ml of solution (1.5g
of antimony, corresponding to 425mg of SbV).
Parasites. The strains IFLA/BR67/PH8 of Leishmania
(Leishmania) amazonensis and MHOM/AR/90LEA4 of
Leishmania (Viannia) braziliensis were used. For both strains,
promastigotes in the stationary phase were obtained from six-dayold in-vitro cultures in Senekjie medium with RPMI1640 (GIBCO,
USA) and 20% fetal bovine serum at 26ºC. The parasites in these
cultures originated from lesions in golden hamsters. Promastigotes
for inoculation were counted in Neubauer chambers.
Animals. Male and female 55 to 65-day-old golden hamsters
(Mesocriscetus auratus) bred at the animal facilities of the
Mario Fatala Chabén National Parasitology Institute were used
in the experiments. Throughout the experiments, the animals
were housed in cages of two to three animals with food and water
ad libitum. In every experiment, each group included at least
five animals.
Infection and treatment. Animals were subcutaneously
inoculated in the right footpad with 1 x 10 6 metacyclic
promastigotes of Leishmania (Leishmania) amazonensis
or 5 x 105 metacyclic promastigotes of Leishmania (Viannia)
braziliensis using a 25g 5/8” needle. Drug treatments were started
immediately after infections, at doses of 450mg/kg/day for five days
a week through an oral cannula for azithromycin and at doses of
60mg/kg/day intramuscularly for five days a week for meglumine
antimoniate, based on previous efficacy reports for hamsters
infected with Leishmania (Viannia) panamensis15. The dose
of azithromycin was chosen based on the maximum dose that was
well tolerated by the animals in a preliminary experiment. The
treatment duration was four weeks for meglumine antimoniate;

628

treatments with azithromycin lasted eight weeks for Leishmania
(Leishmania) amazonensis and five weeks for Leishmania
(Viannia) braziliensis. The differential duration of the treatments
with azithromycin was defined in the experimental design based
on the known duration and aggressiveness of lesions due to
Leishmania (Leishmania) amazonensis compared with
Leishmania (Viannia) braziliensis13.
Lesion size was determined weekly by measuring the thickness
of the infected and contralateral footpad using a digital caliper
(Schwyz Model SC111101E, Switzerland), and the difference
between the footpads was calculated. Leishmania (Leishmania)
amazonensis infections were followed for up to 15 weeks and
Leishmania (Viannia) braziliensis infections for up to 7
weeks.
Dissemination was studied by taking samples from homolateral
popliteal lymph nodes, liver and/or spleen. These tissues
were processed and cultured in Senekjie medium for 30 days,
after which the presence of live parasites was determined.
Semiquantitative parasite counts were made on biopsy tissue of
approximately 10mg that was taken from the lesion at the end of
the experiment. This tissue was weighed and a homogenate was
prepared in a grinder with RPMI1640 containing 20% fetal calf
serum. Serial tenfold dilutions were prepared in 96-well plates
and incubated at 26ºC for 14 days. The highest dilution with
moving parasites was the final titer for each sample. Each biopsy
was cultured in duplicate.
Data analysis. All experiments were performed at least
in duplicate; the data presented represent a summary from all
experiments. The data were analyzed for statistical significance
with the Mann-Whitney test or Student t test when appropriate.
Differences were considered significant with P values of <0.05.
The data analysis was performed using SPSS for Windows, version
12.0 (SPSS Inc, USA).
Results
Effect of azithromycin on Leishmania (Leishmania)
amazonensis infections. Footpad lesions developed in
untreated infected golden hamsters within one week of infection.
Treatment of infected animals with azithromycin had no effect
on the size of the lesions (Figure 1). Semiquantitative analysis of
parasite load in the lesion and cultures of regional lymph nodes at
10 weeks also showed no effect compared with untreated animals
(Table 1). Meglumine antimoniate was effective for controlling
the development of lesions for 10 weeks, after which the lesions
increased in size until the end of the experiment (Figure 1). In a
significant number of animals treated with meglumine antimoniate,
at 10 weeks postinfection, parasites were not recovered from the
lesions and dissemination was blocked (Table 1). However, at
15 weeks postinfection there was uniform positivity of lesion and
popliteal lymph node cultures in all groups. Dissemination to the
liver was observed in one of the six animals in the untreated control
group and in none of the treated animals (five with meglumine
antimoniate and five with azithromycin) at 10 weeks postinfection,
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P <0.05 between meglumine antimoniate and the other groups from week 4 until
the end of the experiment.
Figure 1 - Effect of treatment with 450mg/kg of oral azithromycin for
8 weeks or 60mg/kg of subcutaneous meglumine antimoniate on the
development of footpad swelling caused by infections with 1 x 10 6
metacyclic promastigotes of Leishmania (Leishmania) amazonensis in
Golden hamsters. Ten animals per group were followed until week 10,
when half were sacrificed and the rest were followed until week 15. The
values represent the mean ± standard deviation difference between the
thickness of the infected and the contralateral footpad.

but this difference did not reach statistical significance. Similarly,
dissemination to the spleen was observed in two of the ten
untreated animals but in none of those treated with meglumine
antimoniate (nine) or azithromycin (ten).
Table 1 - Positive cultures of lesions (skin), regional lymph nodes, liver
and spleen at 10 weeks post infection in animals infected with Leishmania
(Leishmania) amazonensis IFLA/BR67/PH8 and treated with meglumine
antimoniate for 4 weeks or azithromycin for 8 weeks. Data represents
number of positive animals/number of animals in the group.
Lesion
Lymph node
Spleen

*
*

15

Time post-infection (weeks)

Liver

Control
Meglumine antimoniate
Azithromycin

3

10

Footpad lesion size (mm)

Footpad lesion size (mm)

4

Control
Meglumine antimoniate
Azithromycin

Control

Meglumine antimoniate

Azithromycin

10/10

5/10*

9/9

8/10

2/10**

6/8

1/6

0/5

0/5

2/10

0/10

0/9

1

2

3

4

Time post-infection (weeks)

* p <0.05 for comparisons between all three groups.
Figure 2 - Effect of treatment with 450mg/kg of oral azithromycin for
5 weeks or 60mg/kg of subcutaneous meglumine antimoniate for 4
weeks on the development of footpad swelling caused by infections with
5 x 105 metacyclic promastigotes of Leishmania (Viannia) braziliensis in
Golden hamsters. Ten animals per group were followed throughout each
of the 2 repetitions of the experiment. The values represent the mean
± standard deviation difference between the thickness of the infected
and the contralateral footpad.
Table 2 - Positive cultures of lesions (skin) regional lymph nodes and
liver at 7 weeks post infection in animals infected with Leishmania
(Viannia) braziliensis MHOM/AR/90LEA4 and treated with meglumine
antimoniate for 4 weeks or azithromycin for 5 weeks. No significant
differences between groups were identified. Data represents number
of positive animals/number of animals in the group.
Control

Meglumine antimoniate

Azithromycin

Lesion

16/16

14/18

13/14

Lymph node

12/16

10/18

11/14

0/16

1/18

0/14

Liver

Discussion

*p<0.01 compared to other 2 groups.
**p=0.01 compared to control and 0.02 compared to azithromycin.

Effect of azithromycin on Leishmania (Viannia)
braziliensis infections. Statistically significant increases in
footpad thickness developed at one week postinfection in untreated
animals and in animals treated with azithromycin. At three weeks
postinfection, the animals treated with meglumine antimoniate
developed lesions. Treatments with meglumine antimoniate resulted
in lesions with delayed appearance and lower peak swelling (Figure
2). The animals treated with azithromycin had lesions that were
significantly smaller than those in untreated controls and larger than
those in golden hamsters treated with meglumine antimoniate, from
three weeks postinfection (p = 0.002) until the end of the experiment
(Figure 2). Recovery of viable parasites from the lesions at seven
weeks postinfection was performed without evidence of significant
differences between groups. At seven weeks, dissemination was
confirmed in popliteal lymph nodes homolateral to the lesions in
all groups, without evidence of significant differences between them
(Table 2). Dissemination of parasites to the liver was detected in one
out of 18 animals, in the meglumine antimoniate group, at seven
weeks postinfection (Table 2).

Our results show that Leishmania (Leishmania) amazonensis
infections in golden hamsters are resistant to azithromycin, such
that the treated animals developed infections indistinguishable
from untreated controls. Meglumine antimoniate was used as a
positive control and demonstrated its efficacy in limiting infections.
Control over the parasite was however not absolute, in that
lesions and local lymph nodes were infected with parasites 15
weeks postinfection (11 weeks after treatment completion). This
finding is consistent with previous reports regarding treatment of
Leishmania (Leishmania) amazonensis and other species of
Leishmania with antimony compounds, in hamsters2.
The lesion size in the animals infected with Leishmania
(Viannia) braziliensis was significantly reduced by treatment
with azithromycin and meglumine antimoniate. Azithromycin
was unable to totally block the development of foot pad swelling,
although the lesions were significantly smaller in treated animals
than in untreated controls. These results mirror those seen in
BALB/cByJ mice infected with Leishmania (Leishmania) major
and treated with azithromycin6, in which animals were treated
subcutaneously using regimens of 100 to 200mg/kg/day for
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eight weeks. Meglumine antimoniate was significantly superior
to oral azithromycin for controlling infection by Leishmania
(Viannia) braziliensis. However, as in the case of Leishmania
(Leishmania) amazonensis, lesions developed in the mice
treated with meglumine antimoniate at the end of the experimental
period. This observation confirms previous reports that meglumine
antimoniate does not eliminate all Leishmania parasites from
golden hamsters using similar treatment regimens15.
The use of positive and negative controls gives support to
the conclusions and makes it unlikely that the differences in
the results between the two species described in this report
might be related to the different inoculum used for each species
(1x 106 for Leishmania (Leishmania) amazonensis and 5x105 for
Leishmania (Viannia) braziliensis). The effects of azithromycin
and meglumine antimoniate at higher and lower inoculum doses or
in different therapeutic schedules were not investigated.
The mechanism of action of azithromycin against
Leishmania is unknown. Azithromycin has been shown to
have immunomodulatory effects in humans with bronchiolitis
obliterans4, and treatment of macrophages with azithromycin
enhanced the elimination of fungal pathogens16. Alternatively, it
is possible that azithromycin has direct antimicrobial activity on
the parasites. In the case of pentavalent antimonials, with over
50 years of use for treating leishmaniasis, their mechanism of
action is also still uncertain: both direct and immune-mediated
mechanisms have been implicated9.
In addition to the preclinical studies performed on mice for
evaluating azithromycin against Leishmania parasites6, the clinical
experiences include an uncontrolled study that involved 20 patients
with cutaneous leishmaniasis in an area endemic for Leishmania
(Viannia) braziliensis treated with variable doses of azithromycin
for two to ten days with a cure rate of 85%10. Contrasting with
these findings, in an area endemic for Leishmania (Leishmania)
major in Syria, no cures were recorded among 45 patients with
cutaneous leishmaniasis using ten-day cycles of azithromycin1.
Three cases of mucosal leishmaniasis with contraindications for
the use of antimonials were successfully treated with three cycles
of ten days of azithromycin in Brazil12.
Based on the discrepant responses of these species to
azithromycin, clinical trials aimed at testing the findings from the
current study must take into consideration the species involved in
the treated patients. In conclusion, azithromycin has activity against
Leishmania (Viannia) braziliensis but not against Leishmania
(Leishmania) amazonensis in golden hamsters. This activity is
inferior to meglumine antimoniate for lesion control, and yet both
drugs failed to eliminate all parasites from the lesions. Further
studies should evaluate the clinical use of azithromycin as an oral
option for treating American cutaneous leishmaniasis caused by
Leishmania (Viannia) braziliensis.

with the illustrations. This study was supported by an educational
grant from Pfizer.
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